Feasibility and toxicity of chemoembolization for children with liver tumors

Marcio Malogolowkin, Philip Stanley, David A. Steele, Jorge A. Ortega

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. Patients and Methods: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. Results: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. Conclusion: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)1279-1284
Number of pages6
JournalJournal of Clinical Oncology
Volume18
Issue number6
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Liver
Neoplasms
Hepatoblastoma
Hepatocellular Carcinoma
alpha-Fetoproteins
Transaminases
Bilirubin
Sarcoma
Nausea
Vomiting
Disease Progression
Fever
Pediatrics
Drug Therapy
Pain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Feasibility and toxicity of chemoembolization for children with liver tumors. / Malogolowkin, Marcio; Stanley, Philip; Steele, David A.; Ortega, Jorge A.

In: Journal of Clinical Oncology, Vol. 18, No. 6, 01.01.2000, p. 1279-1284.

Research output: Contribution to journalArticle

Malogolowkin, Marcio ; Stanley, Philip ; Steele, David A. ; Ortega, Jorge A. / Feasibility and toxicity of chemoembolization for children with liver tumors. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 6. pp. 1279-1284.
@article{4b09aefd0c9c4ba09c84d0a1c8934f00,
title = "Feasibility and toxicity of chemoembolization for children with liver tumors",
abstract = "Purpose: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. Patients and Methods: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. Results: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. Conclusion: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children. (C) 2000 by American Society of Clinical Oncology.",
author = "Marcio Malogolowkin and Philip Stanley and Steele, {David A.} and Ortega, {Jorge A.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1200/JCO.2000.18.6.1279",
language = "English (US)",
volume = "18",
pages = "1279--1284",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Feasibility and toxicity of chemoembolization for children with liver tumors

AU - Malogolowkin, Marcio

AU - Stanley, Philip

AU - Steele, David A.

AU - Ortega, Jorge A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Purpose: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. Patients and Methods: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. Results: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. Conclusion: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. Patients and Methods: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. Results: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. Conclusion: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034116137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034116137&partnerID=8YFLogxK

U2 - 10.1200/JCO.2000.18.6.1279

DO - 10.1200/JCO.2000.18.6.1279

M3 - Article

C2 - 10715298

AN - SCOPUS:0034116137

VL - 18

SP - 1279

EP - 1284

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -